Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - February 2013


Phase I & IIA clinical trials

27 Feb 2013 - 28 Feb 2013 - London, UK



Bookmark and Share


The Phase I & IIa Clinical Trials conference has been revamped for 2013 to provide you with two highly focused and high quality streams, providing answers to the latest questions in early phase drug development. This year we will be looking at how we can design more effective and efficient Phase I & IIa clinical trials, benchmarking against current industry models to find out what works best and how we can adapt this to our trials going forward.

6 Reasons why you MUST attend this conference……

Over 160 attendees from small, medium and large pharma and biotech companies 

Wine Casino networking event - your opportunity to meet new faces in early phase clinical development 

8 interactive sessions: Don’t miss our regulatory Q&A to get the latest updates on EU and US regulations and find out how you can remain compliant 

70 speakers including 6 Vice Presidents, 10 Heads and 15 Directors from pharma and 10 CEOs and CMOs from biotech 

Increased focus on biotech  - with speakers from 13 leading biotech companies 

2 re-engineered streams including one stream entirely dedicated to outsourcing and patient recruitment in early phase trials 

Please quote CQ4170TN when booking your place.

For more information and to download the conference brochure, please visit: 

http://www.informa-ls.com/CQ4170TN




Further information
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!